Tevogen’s Chief Scientific Officer speak on pipeline

Tevogen Bio Holdings announces Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer, explained the company’s oncology pipeline strategy. “CTLs can be used for cancer treatments in several ways. Certain cancers are virally driven and can be targeted very similarly to targeting other viral infections. Our overwhelmingly positive experience with TVGN 489 gives us confidence that such an approach would succeed. For example, virtually all cases of cervical cancer are caused by Human Papilloma Virus. After being infected by HPV, the virus remains in the cells before and after transformation to cancer. The virus can be targeted by CTLs before cancer transformation as a preventative step or after transformation as part of treatment. This approach could spare many women from surgical procedures and, in other cases, reduce the size and scope of a surgery to something more modest. In advanced cases, CTLs could be combined with other treatments.” Dr. Flomenberg goes on to explain, “Some cancers that are not triggered by viruses can be targeted in other ways. The simplest next step would be to selectively coat the tumor cells with viral targets and use anti-viral CTLs to then eliminate them. Additional approaches are in development to take this approach even further in the treatment of other cancers.”